Relief Therapeutics Holding SA (OTCMKTS:RLFTF – Get Free Report) was the recipient of a large decrease in short interest in April. As of April 30th, there was short interest totaling 7,692 shares, a decrease of 63.5% from the April 15th total of 21,047 shares. Based on an average daily trading volume, of 4,461 shares, the days-to-cover ratio is presently 1.7 days.
Relief Therapeutics Trading Up 11.4%
OTCMKTS RLFTF traded up $0.05 during trading hours on Friday, hitting $0.54. 1,851 shares of the company were exchanged, compared to its average volume of 3,474. The stock has a 50-day moving average price of $0.50 and a 200 day moving average price of $1.79. Relief Therapeutics has a 52 week low of $0.33 and a 52 week high of $4.88.
Relief Therapeutics Company Profile
Relief Therapeutics AG is a clinical?stage biopharmaceutical company focused on the development of novel therapies for rare and critical care indications. Headquartered in Geneva, Switzerland, the company leverages its expertise in peptide biology to address diseases with high unmet need, including acute respiratory distress syndrome (ARDS) and other serious pulmonary and inflammatory conditions.
The company’s lead product candidate, RLF?100 (aviptadil), is a synthetic formulation of vasoactive intestinal peptide (VIP) being evaluated for the treatment of ARDS and COVID-19–associated respiratory failure.
Read More
- Five stocks we like better than Relief Therapeutics
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Relief Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relief Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
